Previous 10 | Next 10 |
The first patients have been enrolled in ARCA biopharma's (ABIO) ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 (AB201) as a potential treatment for patients hospitalized with COVID-19.The first patient was enrolled at the University of Colorado Hospital on December 10, 20...
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines rNAPc2 is the only novel compound being developed for COVID-19 Associated Coagulopathy Topline trial data anticipated in the second quarter of 2021 ...
WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company’s offices located at 10170 Church Ra...
ARCA Biopharma (ABIO) jumped 5.5% in today's trade for its highest close in a month after saying it received Fast Track designation from the U.S. Food and Drug Administration for its AB201 experimental COVID-19 treatment.ARCA says it plans to start a Phase 2b clinical trial of AB201 next mont...
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not AB201 is the only novel compound being developed for COVID Associated Coagulopathy Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December...
ARCA biopharma (ABIO): Q3 GAAP EPS of -$0.33.Cash and cash equivalents of $51.1M.Shares are up 0.5% PM.Press Release. For further details see: ARCA biopharma reports Q3 results
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID 19 anticipated in fourth quarter Topline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02, 2020 (G...
Gainers: Taiwan Liposome (TLC) +36%. Ocular Therapeutix (OCUL) +21%. LogicBio Therapeutics (LOGC) +11%. American Well (AMWL) +11%. Tiziana Life Sciences (TLSA) +11%.Losers: Enlivex Therapeutics (ENLV) -12%. Aytu BioScience (AYTU) -12%. Xtant Medical (XTNT) -11%. ARCA bioph...
ARCA Biopharma (ABIO) 6% in premarket, as the FDA has signed off its Phase 2b/3 sequential trial evaluating AB201 (rNAPc2) as a potential treatment for patients hospitalized with COVID-19.The company plans to commence the trial, ASPEN-COVID-19, in ~100 subjects during...
Initiation of Phase 2b clinical trial anticipated in Q4 2020 Trial to enroll approximately 100 patients hospitalized with COVID-19 Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceu...
News, Short Squeeze, Breakout and More Instantly...
Bogota Financial Corp. (BSBK) is expected to report for Q2 2024 Capital Product Partners L.P. (CPLP) is expected to report $0.17 for Q2 2024 Colgate-Palmolive Company (CL) is expected to report $0.87 for Q2 2024 ARCA biopharma Inc. (ABIO) is expected to report for Q2 2024 Barnes G...
Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q2 2024 Electrolux AB ADR (ELUXY) is expected to report $-0.18 for Q2 2024 Coca Cola Femsa S.A.B. de C.V. American Depositary Shares each representing 10 Units (each Unit consists of 3 Series B Shares and 5 Series L S...
NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sale...